Technical Analysis for DVAX - Dynavax Technologies Corporation

Grade Last Price % Change Price Change
grade F 6.51 2.36% 0.15
DVAX closed up 2.36 percent on Tuesday, April 23, 2019, on 67 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Earnings due: May 6

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical DVAX trend table...

Date Alert Name Type % Chg
Lower Bollinger Band Walk Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Closing Low Bearish 2.36%
Lower Bollinger Band Walk Weakness 2.36%
Below Lower BB Weakness 2.36%
Down 3 Days in a Row Weakness 2.36%
Down 4 Days in a Row Weakness 2.36%
Down 5 Days in a Row Weakness 2.36%
Lower Bollinger Band Touch Weakness 2.36%

Older signals for DVAX ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious and inflammatory diseases. It develops product candidates based on the use of immunostimulatory sequences and immunoregulatory sequences. Its lead product candidate is HEPLISAV, a Phase III investigational adult hepatitis B vaccine. The company also develops DV1179, a Phase I bifunctional inhibitor of TLR7 and TLR9 for the treatment of autoimmune and inflammatory diseases; and AZD1419, a preclinical drug candidate for the treatment of asthma. It has a strategic alliance with GlaxoSmithKline to discover, develop, and commercialize TLR inhibitors; and a research collaboration and license agreement with AstraZeneca AB for the discovery and development of TLR9 agonist-based therapies for the treatment of asthma and chronic obstructive pulmonary disease. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was founded in 1996 and is based in Berkeley, California.
Health Biopharmaceutical Pharmaceutical Industry Asthma Chronic Obstructive Pulmonary Disease Astrazeneca Autoimmune And Inflammatory Diseases Treatment Of Autoimmune And Inflammatory Diseases Tlr7 Tlr9
Is DVAX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 20.1
52 Week Low 6.22
Average Volume 1,186,957
200-Day Moving Average 11.0523
50-Day Moving Average 8.3042
20-Day Moving Average 6.9765
10-Day Moving Average 6.725
Average True Range 0.3653
ADX 45.83
+DI 10.5853
-DI 30.0115
Chandelier Exit (Long, 3 ATRs ) 6.6441
Chandelier Exit (Short, 3 ATRs ) 7.3159
Upper Bollinger Band 7.647
Lower Bollinger Band 6.306
Percent B (%b) 0.15
BandWidth 19.221673
MACD Line -0.4866
MACD Signal Line -0.5044
MACD Histogram 0.0177
Fundamentals Value
Market Cap 357 Million
Num Shares 54.8 Million
EPS -2.42
Price-to-Earnings (P/E) Ratio -2.69
Price-to-Sales 143.85
Price-to-Book 7.89
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.95
Resistance 3 (R3) 6.92 6.76 6.87
Resistance 2 (R2) 6.76 6.65 6.77 6.85
Resistance 1 (R1) 6.63 6.58 6.70 6.66 6.82
Pivot Point 6.47 6.47 6.50 6.48 6.47
Support 1 (S1) 6.34 6.36 6.41 6.37 6.20
Support 2 (S2) 6.18 6.29 6.19 6.17
Support 3 (S3) 6.05 6.18 6.15
Support 4 (S4) 6.08